Table 1 Profile of background factors by temperature increase and oximetry decrease 24-h post-infusion of casirivimab-imdevimab
From: Casirivimab-imdevimab neutralizing SARS-CoV-2: post-infusion clinical events and their risk factors
Total | Temp+ | Ox94 | |||||
|---|---|---|---|---|---|---|---|
Factor | Division (Unit) | N = 96 | Median (Interquartile range) | N = 47 | Median (Interquartile range) | N = 21 | Median (Interquartile range) |
Sex | Male | 51 | 29 | 13 | |||
Female | 45 | 18 | 8 | ||||
Smoking | Yes | 59 | 29 | 12 | |||
Never | 37 | 18 | 9 | ||||
CT Bilateral | Bilateral | 34 | 21 | 15 | |||
Otherwise | 62 | 26 | 6 | ||||
2-Time Vaccination | Yes | 15 | 2 | 2 | |||
No | 81 | 45 | 19 | ||||
Age | (Years) | 55.5 (46.5–63.0) | 53.0 (45.0–61.0) | 56.0 (51.0–67.0) | |||
Body MassIndex | (kg/m2) | 23.25 (20.75–25.55) | 24.30 (20.30–26.90) | 24.80 (22.65–26.75) | |||
Symptomatic | (Day) | 3.0 | 3.0 (2.0–4.0) | 4.0 (1.0–5.0) | |||
PreTemp | Centigrade | 36.9 (36.50–37.30) | 36.7 (36.50–37.30) | 36.70 (36.50–37.25) | |||
PreOx | (%) | 97.0 | 97.0 (96.0–97.0) | 96.0 (96.0–97.0) | |||
WhileBlood Cell | (×103) | 4.62 | 4.96 (3.99–5.92) | 4.79 (3.88–6.24) | |||
Neutrophil | (%) | 65.70 | 66.60 (57.60–71.4) | 67.90 (54.60–74.10) | |||
Lymphocytes | (%) | 23.95 | 22.90 (18.30–31.90) | 23.60 (20.00–36.25) | |||
C-reactive protein | (mg/dl) | 0.69 | 0.61 (0.21–2.91) | 3.06 (0.47–5.77) | |||
Total Bilirubin | (mg/dl) | 0.60 | 0.60 (0.40–0.70) | 0.60 (0.50–0.75) | |||
Creatinine | (mg/dl) | 0.810 | 0.860 (0.74–1.00) | 0.810 (0.72–1.02) | |||
Platelet | (×103) | 186.5 | 185.0 (154.0–231.0) | 184.0 (140.0–223.5) |